SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Emisphere -- Ignore unavailable to you. Want to Upgrade?


To: Harold Engstrom who wrote (234)10/29/2005 6:52:58 PM
From: hmpa  Respond to of 272
 
I don't believe there is much from heparin in company's current valuation. I'd feel more comfortable if they quit both heparin and insulin and "go virtual" waiting for Novartis and Roche royalties which could be mighty juicy (low double-digit range for very major products). As a short-term stock price driver pending court decision in their case vs LLY (if decided clearly one way or another) will probably be bigger than heparin results.